Join our daily newsletter At The Bell to receive exclusive market insights
- Immuron (IMC) is granted a European patent for compositions and methods for treating travellers’ diarrhoea
- Immuron’s Travelan is an orally administered immunotherapy that reduces the likelihood of contracting travellers’ diarrhoea – proven to be more effective than commonly prescribed antibiotics
- Immuron is now focused on validating the patent in multiple European countries, with the processes for doing so underway
- The new European patent follows patents approved in Australia, India, Canada, and the United States
- Immuron shares were up 20.8 per cent to 14.5 cents
Immuron (IMC) has been granted a European patent for compositions and methods for treating travellers’ diarrhea.
Travellers’ diarrhoea is an infectious diarrhoea commonly reported by tourists visiting developing countries or troops deployed overseas and can result in post-infectious irritable bowel syndrome and several post-infectious autoimmune diseases. Symptoms include loose, watery, and occasionally bloody stools, abdominal cramping, bloating and fever.
The first line of treatment for infectious diarrhoea is typically antibiotics, however in the last decade, several enteric pathogens have built up an increasing resistance to commonly prescribed antibiotics.
Immuron’s Travelan is an orally administered passive immunotherapy that reduces the likelihood of contracting travellers’ diarrhea.
The treatment is a highly purified form of hyper-immune bovine antibodies, which, when taken with meals, bind to diarrhea-causing bacteria to prevent colonisation and the pathology associated with diarrhea.
Immuron said a preventative treatment that protects against enteric diseases is a high priority objective for the US Military, making its treatment for travellers’ diarrhoea essential.
Immuron’s European Patent 3159357 was entitled “Composition and method for the treatment and prevention of enteric bacterial infections”, and was granted on January 5.
Immuron is now focused on validating the patent in France, Spain, Sweden, Austria, Germany, Denmark, Finland, Greece and the United Kingdom, with the processes for doing so already underway.
The new European patent follows patents approved in Australia, India, Canada, and the United States.
Immuron shares were up 20.8 per cent to 14.5 cents.
